NCT04596878View on ClinicalTrials.gov

Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV

PHASE2CompletedINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

November 19, 2020

Primary Completion Date

May 18, 2022

Study Completion Date

May 11, 2023

Conditions
Group B Streptococcal Infection
Interventions
BIOLOGICAL

GBS-NN/NN2

GBS-NN/NN2 bound to Alhydrogel as an adjuvant.

BIOLOGICAL

Placebo

Normal Saline 0.9%

Trial Locations (3)

Unknown

Empilweni Services and Research Unit (ESRU), Rahima Moosa Mother and Child Hospital, Johannesburg

University of the Witwatersrand, Johannesburg (Respiratory and Meningeal Pathogens Research unit), Johannesburg

MUJHU Research Collaboration/MUJHU Care Ltd, Kawempe National Referral Hospital, Kawempe

Sponsors

Lead Sponsor

Minervax ApS
All Listed Sponsors
collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

lead

Minervax ApS

OTHER

NCT04596878 - Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV | Biotech Hunter | Biotech Hunter